Deerfield Management Company, L.P. (Series C) Foghorn Therapeutics Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,518,500 shares of FHTX stock, worth $24.5 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
2,518,500Holding current value
$24.5 Million% of portfolio
0.3%Shares
3 transactions
Others Institutions Holding FHTX
# of Institutions
72Shares Held
32.8MCall Options Held
6KPut Options Held
1.8K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$123 Million8.71% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$51.5 Million0.93% of portfolio
-
Raymond James & Associates St Petersburg, FL2.34MShares$22.7 Million0.01% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$15.3 Million1.14% of portfolio
-
Black Rock Inc. New York, NY1.55MShares$15 Million0.0% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $405M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...